ベータ
治験レーダーAI
治験 NCT06768827 (NMoO)(対象:Obesity and Overweight、インスリン抵抗性、Obesity and Obesity-related Medical Conditions)は募集未定です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。
フィルター基準に一致する試験が1件見つかりました
タイル表示

New Mechanisms of Obesity (NMoO)

募集未定
治験(臨床試験)の詳細は主に英語で提供されています。しかし、治験レーダーAIが支援できます!「治験を説明」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT06768827 (NMoO) は 介入研究 臨床試験 で、Obesity and Overweight、インスリン抵抗性、Obesity and Obesity-related Medical Conditions に関するものです。現在は 募集未定 で、2025年11月1日 に開始予定です。55 名の参加者 の募集が計画されています。この治験は イェール大学 によって主催され、2030年3月31日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2025年9月26日 です。
概要
Given the pervasiveness of Pediatric Obesity, it is imperative to understand its pathophysiology and develop alternative strategies to reverse this condition. Herein, investigators propose to elucidate the interaction between colonic fermentation and insulin resistance in modulating metabolism in youth with obesity.
詳細説明
Pediatric obesity is a major health burden affecting millions of children and adolescents as it predisposes to the development of cardio-metabolic diseases early in life, such as insulin resistance, fatty liver disease and type 2 diabetes. Investigators have recently completed a series of studies to understand the relationship between the intestinal microbial activity and human metabolism in youth. It was observed that intestinal fermentation, a process through which fermentable carbohydrates are processed by intestinal bacteria, results in a variety of biological responses aimed at protecting the human body from developing obesity and some of its metabolic complications, such as insulin resistance and ectopic fat accumulation. In particular, investigators observed that intestinal fermentation causes 1- a reduction of plasma free fatty acids (FFA), due to the inhibition of adipose tissue lipolysis (ATL); 2- a marked entero-endocrine response to reduce appetite, characterized by an increase in the production of peptide YY (PYY) and glucagon-like peptide1 (GLP-1) and a reduced production of ghrelin. In addition, investigators observed that some intestinal fermentation responses are impaired in youth with obesity and insulin resistance (OIR). In light of this evidence, the current proposal will address: 1- how adipose tissue lipolysis response to intestinal fermentation is affected by insulin resistance; 2- whether changes in ATL, observed when fermentation occurs, are also associated with a reduction of glycerol derived neo-gluconeogenesis; 3- if physical activity may restore the entero-endocrine and adipose tissue response to intestinal fermentation in youth with insulin resistance. This is the first study to test the effect of insulin resistance on the relationship between intestinal microbial metabolic activity and human metabolism (namely adipose tissue lipolysis, gluconeogenesis and entero-endocrine response). The results obtained will provide fundamental insight into how insulin resistance occurring in youth with obesity affects the metabolic response to fermentable carbohydrates. In fact, despite the large body of literature showing an association between intestinal microbial fermentation and human metabolism, how and whether insulin resistance may modulate this association remains unknown.
公式タイトル

Pathogenic Mechanisms of Obesity and Its Cardiometabolic Complications

疾患/病気
Obesity and Overweightインスリン抵抗性Obesity and Obesity-related Medical Conditions
その他の研究識別子
NCT番号
開始日
2025-11
最終更新日
2025-09-26
終了予定日
2030-03-31
目標参加者数
55
試験の種類
介入研究
治験の相・段階
該当なし
状況
募集未定
キーワード
Obesity
Youth
Insulin Resistance
Intestinal Fermentation
主目的
基礎研究
割付方法
無作為化
介入モデル
並行割当
盲検化
なし(非盲検)
群(アーム)/介入
参加グループ/群介入/治療法
実験的Remote physical exercise
Lactulose Oral Product
Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
実薬対照薬Control physical excercise
Lactulose Oral Product
Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
主要評価項目
評価指標指標の説明時間枠
CHANGES IN ADIPOSE TISSUE LIPOLYSIS (ATL)
Changes in adipose tissue lipolysis occurring after colonic fermentation (stimulated by lactulose) will be compared between youth with obesity and insulin resistance (OIR) and with obesity and without insulin resistance (OIS). Lipolysis will be measured by using change in D5-glycerol concentration.
6 hours
CHANGES IN GLUCONEOGENESIS
Gluconeogenesis (GLC) will be measured using change in deuterium oxide concentration after colonic fermentation due to lactulose ingestion and compared between OIS and OIR.
6 hours
CHANGES IN ADIPOSE TISSUE LIPOLYSIS (ATL)
Changes in ATL due to colonic fermentation will be measured in two groups of OIR youth. One group will undergo physical activity for 12 weeks and another group will undergo a control intervention. Lipolysis will be measured by using change in D5-glycerol concentration.
Baseline and 12 weeks
副次評価項目
評価指標指標の説明時間枠
CHANGES IN PEPTIDE YY (PYY) concentration
Changes in PYY concentration after lactulose intervention will be compared between OIS and OIR.
Baseline and 12 weeks
CHANGES IN GHRELIN concentration
Changes in GHRELIN concentration after lactulose intervention will be compared between OIS and OIR.
Baseline and 12 weeks
適格基準

対象年齢
小児, 成人
試験の最低年齢
15 Years
対象性別
全て
  • Age 15 to 22 years
  • In puberty (girls and boys: Tanner stage III-V);
  • BMI >85th

  • Pregnancy;
  • endocrinopathies (e.g., Cushing syndrome);
  • substance abuse;
  • medications affecting insulin resistance such as metformin, GLP-1 analogues; -
  • high fibers intake (> 30g/day) as assessed by a 3-day food record.
  • National Institutes of Health (NIH) logoNational Institutes of Health (NIH)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) logoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
試験中央連絡先
連絡先: NICOLA SANTORO, MD, PhD, 2037852819, [email protected]
1 1カ国の場所

Connecticut

Yale University, New Haven, Connecticut, 06520, United States